BRD4 and Hepatic fibrosis: Given the fact that inhibition of bromodomain-containing protein 4, another member of BET proteins, abrogated activation of HSCs and even reversed liver fibrosis in mice treated with CCl4 (Ding et al., 2015), BET inhibitors should be evaluated for the treatment of liver fibrosis.